RapidAI Overview
Pro stress-test →RapidAI is the global leader in using AI to combat life-threatening vascular and neurovascular conditions. The company delivers deep clinical AI on an enterprise platform, enhancing AI clinical assessment and transforming care across service line programs. Based on intelligence gained from over 10 million scans in more than 2,000 hospitals in over 100 countries, the Rapid platform transforms care coordination, offering care teams a level of patient visibility never before possible.
Strategic Profile
Pro stress-test →As a clinician-founded company, RapidAI ensures its tools meet practical needs by using curated datasets and advanced image processing techniques. Frost & Sullivan ranks RapidAI's enterprise platform ahead of 96% in the industry. RapidAI is used by more than 2,500 hospitals in over 100 countries and backed by 700+ clinical studies, including research that helped expand national stroke-treatment guidelines.
Competitive Landscape
Pro stress-test →RapidAI's top competitors include Viz.ai, Brainomix and Cerebriu. Real-world data from the European Stroke Organisation Conference suggests RapidAI's software more accurately identifies medium vessel occlusions (MeVOs) than Viz.ai in stroke patients. RapidAI ranks 3rd amongst 66 active competitors and stands 2nd in total funding among them.
Industry Context
RapidAI operates in Clinical AI platforms for medical imaging.
Key facts
Founded: 2012 · Headquarters: San Mateo, US · Employees: 267 (as of March 2026)